TNO155
CAY-32525-1 1 mg
Data Sheet: 
SDS:
SDS:
CAS
1801765-04-7
Formulation
A crystalline solid
Purity
≥98%
MW
421,9
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
TNO155 is an orally bioavailable allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC50 = 0.011 µM).{61227} It is selective for SHP-2 over a panel of 52 kinases and phosphatases (IC50s = >10 µM for all). TNO155 decreases phosphorylation of ERK in, and inhibits proliferation of, KYSE-520 human esophageal cancer cells (IC50s = 0.011 and 0.1 µM, respectively). It acts synergistically with dabrafenib (Item No. 16989) and trametinib (Item No. 16292) to inhibit proliferation of B-RAFV600E-expressing HT-29, RKO, and MDST8 colorectal cancer cells.{61228} TNO155 (2.5, 10, and 20 mg/kg twice per day) reduces tumor growth in a KYSE-520 mouse xenograft model.{61227}
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
